Actuate Therapeutics, Inc. (ACTU) Key Metrics
ACTU valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $14.5M
- Enterprise value
- $23.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 17.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.20
ACTU key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsACTU valuation Price multiples at each fiscal year-end price.
ACTU returns How much profit the business earns on the capital it uses.
ACTU per-share figures Results divided by the shares outstanding at year-end.
ACTU financial health Debt, liquidity and how easily interest is covered.
ACTU valuation history
ACTU returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ACTU debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ACTU price vs earnings per share
ACTU key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $128.7M | $155.3M | — | — |
| Enterprise value | $115.9M | $147.1M | — | — |
| Price / book | 16.2 | — | — | — |
| Earnings yield | −17.3% | −17.6% | — | — |
| Free cash flow yield | −14.9% | −14.1% | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — |
| Share price at fiscal year-end | $6.12 | $7.96 | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.06 | −$1.40 | −$1.65 | −$1.34 |
| Operating cash flow per share | −$0.91 | −$1.12 | −$1.44 | −$1.18 |
| Free cash flow per share | −$0.91 | −$1.12 | −$1.44 | −$1.18 |
| Cash per share | $0.63 | $0.44 | $0.20 | $1.36 |
| Book value per share | $0.38 | $0.01 | −$6.63 | $0.99 |
| Tangible book value per share | $0.38 | $0.01 | −$6.63 | $0.99 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.02 | $0.02 | — | $0.03 |
| Shares outstanding | 21.0M | 19.5M | 15.0M | 15.0M |
| Change in shares outstanding | +7.7% | +29.8% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −553.7% | — | — | −135.9% |
| Return on assets (ROA) | −190.4% | −443.2% | −210.8% | −98.4% |
| Return on tangible assets | −158.4% | −292.8% | −826.0% | −98.4% |
| Financial health | ||||
| Total debt | $404,991 | $404,991 | — | $404,991 |
| Cash & short-term investments | $13.2M | $8.6M | $3.0M | $20.4M |
| Net debt | −$12.8M | −$8.2M | −$3.0M | −$20.0M |
| Debt / equity | 0.05 | 3.89 | — | 0.03 |
| Debt / assets | 0.03 | 0.04 | — | 0.02 |
| Net debt / EBITDA | — | — | −10.84 | −315.13 |
| Current ratio | 2.39 | 1.05 | 0.43 | 4.71 |
| Quick ratio | 2.39 | 1.05 | 0.43 | 4.71 |
| Interest coverage | — | — | -572.3 | — |
| Working capital | $7.9M | $405,397 | −$3.9M | $16.1M |
| Invested capital | −$4.8M | −$8.1M | −$102.6M | −$5.2M |
| Tangible asset value | $7.9M | $104,186 | −$99.6M | $14.8M |
| Net current asset value | $7.5M | −$6,362 | −$99.6M | $14.8M |
| Graham net-net per share | $0.34 | −$0.03 | −$6.63 | $0.98 |
| Capital allocation | ||||
| Share buybacks (net) | — | $0 | — | — |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.7M | $2.7M | $2.8M | $2.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ACTU's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ACTU valuation and financial ratios
Actuate Therapeutics earned a return on equity of −553.7% in fiscal 2025. It ended the year with $0.4 million of debt and $13.2 million in cash and short-term investments, a net cash position of $12.8 million.
See the ACTU income statement, the ACTU chart for price history, or the ACTU stock overview for the latest quote and news.
ACTU key metrics FAQ
What is Actuate Therapeutics's return on equity?
Actuate Therapeutics's return on equity (ROE) was −553.7% in fiscal 2025: net income of -$22.2 million on average shareholders' equity of $4.0 million.
How much debt does Actuate Therapeutics have?
Actuate Therapeutics had total debt of $0.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Actuate Therapeutics's free cash flow yield?
Actuate Therapeutics generated -$19.2 million of free cash flow in fiscal 2025, a free cash flow yield of −14.9% on its market value at year-end ($128.7 million).
What is Actuate Therapeutics's current ratio?
Actuate Therapeutics's current ratio was 2.39 at the end of fiscal 2025: current assets were 2.39 times current liabilities.